<DOC>
	<DOCNO>NCT01704898</DOCNO>
	<brief_summary>The primary objective study determine average bioequivalence generic efavirenz 600 mg tablet ( test formulation ) compare Stocrin ( R ) 600 mg tablet ( Reference formulation ) .The study design open label , randomize , crossover , 2-treatments , 2-period , 2-sequence , single dose pharmacokinetic study conduct healthy volunteer . Subjects randomize receive generic efavirenz 600 ( Test formulation ) Stocrin ( R ) 600 tablet ( Reference formulation ) study day 1 ( period 1 ) . Subjects undergo 24 hour intensive pharmacokinetic evaluation ingest single dose either Test Reference formulation . Subjects provide additional pharmacokinetic sample 36 , 48 , 72 , 120 192 hour postdose , respectively . Subjects complete wash period day 8 day 28 wich study drug ingest . On day 29 subject ingest either Test Reference formulation ( opposite formulation receive period 1 ) . All subject undergo another 24 hour intensive pharmacokinetic evaluation pharmacokinetics sample day 36 , 48 , 72 , 120 , 192 po dose , respectively . Adverse event concomitant medication document throughout study .</brief_summary>
	<brief_title>Efavirenz Comparative Bioavailability</brief_title>
	<detailed_description>The primary objective study determine average bioequivalence generic efavirenz 600 mg tablet ( test formulation ) compare Stocrin ( R ) 600 mg tablet ( Reference formulation ) .The study design open label , randomize , crossover , 2-treatments , 2-period , 2-sequence , single dose pharmacokinetic study conduct healthy volunteer . Subjects randomize receive generic efavirenz 600 ( Test formulation ) Stocrin ( R ) 600 tablet ( Reference formulation ) study day 1 ( period 1 ) , undergo 24 hour intensive pharmacokinetic evaluation ingest single dose either Test Reference formulation . Additional pharmacokinetic sample 36 , 48 , 72 , 120 192 hour postdose drawn . Subjects complete wash period form day 8 day 28 study drug ingest . On day 29 ( period 2 ) ingest either Test Reference formulation ( opposite formulation receive period 1 ) . All subject undergo another 24 hour intensive pharmacokinetic evaluation pharmacokinetics sample day 36 , 48 , 72 , 120 , 192 pos-dose , respectively , drawn . Adverse event concomitant medication document throughout study . The sample size 28 base 15 % dropout rate ( due lose follow-up , treatment discontinuation , etc . ) Since investigator expect four subject complete study,24 evaluable subject finally expect . If discontinuation rate great 15 % , investigator continue enroll get 24 evaluable subject . The primary endpoint determine average bioequivalence Test Reference formulation efavirenz accord FDA guidance bioequivalence test . The ratio Test Reference formulation mean efavirenz AUC0-192 , AUC0-inf Cmax 90 % confidence interval around mean ratio determine . Average bioequivalence meet 90 % confidence interval around de AUC Cmax mean ratio efavirenz fall within FDA 's predefined limit 0.80 1.25 . Safety evaluate administer questionnaire subject study . This questionnaire list frequent adverse effect already describe innovator ( Stocrin ( R ) ) . Safety also evaluate vital sign recording , lab test limit fix study protocol Psychiatric Evaluations screening , wash period 15 day last administration study medication .</detailed_description>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Male , Caucasians Age &gt; =18 &lt; =50 , BMI &gt; 18 BMI &lt; 30 kg/m2 HIV1 negative , B Hepatitis negative , C Hepatitis negative . Able give consent , Non/lightsmoking , Lab screen EKG within limit stipulate protocol . Healthy determine medical examination . Subjects current past history psychiatric disorder . Subjects receive prescription overthecounter product . Subjects use form recreational drug . Subjects eat grapefruit drunk grapefruit juice last 15 day administration study drug . Subjects xanthine contain beverage ( mate , coffee , tea , chocolate , etc . ) 48 previous study drug administration . Subjects history hepatic disease , renal disease , GI diseases , chronic infectious disease , heart disease , lung disease , neurologic disease , endocrine disease , etc . Subjects suffer acute disease screen checkin . Alanine S. Transaminase ( AST ) /Alanine L. Transaminase ( ALT ) &gt; 3 time upper limit normal ( ULN ) . Bilirubin &gt; 2.5 time ULN . Amylase &gt; 2 time ULN . Absolute Neutrophil Count &lt; 1000/mL . Hgb &lt; 9.0 g/dl . Platelets &gt; 50.000 cell/mm3 , Serum Creatinine &gt; 2.5 mg/dl</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>efavirenz</keyword>
	<keyword>bioequivalence</keyword>
	<keyword>fast</keyword>
	<keyword>healthy volunteer</keyword>
</DOC>